Teresa Helsten
Overview
Explore the profile of Teresa Helsten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Puhalla S, Dieras V, Arun B, Kaufman B, Wildiers H, Han H, et al.
Clin Cancer Res
. 2021 Jun;
27(18):4983-4993.
PMID: 34131001
Purpose: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (g)-associated breast cancer enrolled in the BROCADE3 trial who received crossover...
12.
Dornisch A, Yang E, Gruspe J, Roesch E, Aristizabal P, Aarons G, et al.
J Adolesc Young Adult Oncol
. 2021 Jan;
10(5):512-520.
PMID: 33470879
Oncofertility care at cancer diagnosis remains underimplemented across oncology and fertility care settings, with limited tools to scale up effective implementation strategies. Using implementation science theory, we systematically assessed factors...
13.
Yee D, DeMichele A, Yau C, Isaacs C, Fraser Symmans W, Albain K, et al.
JAMA Oncol
. 2020 Jul;
6(9):1355-1362.
PMID: 32701140
Importance: Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a...
14.
Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A, et al.
JAMA Oncol
. 2020 Feb;
6(5):676-684.
PMID: 32053137
Importance: Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed. Objective: To determine if pembrolizumab...
15.
Jo Chien A, Tripathy D, Albain K, Fraser Symmans W, Rugo H, Melisko M, et al.
J Clin Oncol
. 2020 Feb;
38(10):1059-1069.
PMID: 32031889
Purpose: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy...
16.
Shatsky R, Parker B, Bui N, Helsten T, Schwab R, Boles S, et al.
Mol Cancer Ther
. 2019 Mar;
18(5):1001-1011.
PMID: 30926636
Clinical-grade next-generation sequencing (NGS) of tissue- and blood-derived circulating tumor DNA (ctDNA) allows assessment of multiple genomic alterations in patients with cancer. We analyzed ctDNA (54-70 genes) in 62 patients...
17.
Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology
Bevers T, Helvie M, Bonaccio E, Calhoun K, Daly M, Farrar W, et al.
J Natl Compr Canc Netw
. 2018 Nov;
16(11):1362-1389.
PMID: 30442736
The NCCN Guidelines for Breast Cancer Screening and Diagnosis have been developed to facilitate clinical decision making. This manuscript discusses the diagnostic evaluation of individuals with suspected breast cancer due...
18.
Park J, Liu M, Yee D, Yau C, J van t Veer L, Fraser Symmans W, et al.
N Engl J Med
. 2016 Jul;
375(1):11-22.
PMID: 27406346
Background: The heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or...
19.
Helsten T, Kato S, Schwaederle M, Tomson B, Buys T, Elkin S, et al.
Mol Cancer Ther
. 2016 May;
15(7):1682-90.
PMID: 27196769
Alterations in the cyclin-dependent kinase (CDK)-retinoblastoma (RB) machinery disrupt cell-cycle regulation and are being targeted in drug development. To understand the cancer types impacted by this pathway, we analyzed frequency...
20.
Helsten T, Elkin S, Arthur E, Tomson B, Carter J, Kurzrock R
Clin Cancer Res
. 2015 Sep;
22(1):259-67.
PMID: 26373574
Purpose: Molecular profiling may have prognostic and predictive value, and is increasingly used in the clinical setting. There are more than a dozen fibroblast growth factor receptor (FGFR) inhibitors in...